News Hub | News Direct

Cutting Through the AEP Clutter

YourUpdateTV

Millions of older Americans rely on Medicare as a crucial support for their health care. Yet, choosing a health plan that fits their needs can be overwhelming, particularly since nearly 90% of adults struggle with understanding health-related information. This can make the Medicare Annual Enrollment Period (AEP) – which runs from October 15 th to December 7 th – feel like an obstacle course Medicare beneficiaries must navigate every year. A video accompaying this release can be found here: https://youtu.be/F-MZ0L3t9Zw Recently, Terri Swanson, President of Medicare for Aetna, a CVS Health company, participated in a nationwide satellite media tour to discuss the annual enrollment period and tips for consumers on how to choose a plan. When selecting a plan, the first thing people should consider is their own health needs, which can help cut through the clutter of information and make a decision that’s right for you. Medicare decisions can be confusing, so it’s important to seek out trusted sources of information and ask yourself some basic questions before choosing a plan. The three main questions people should ask themselves are: Will this plan fit my budget? This includes the monthly premium, as well as out-of-pocket costs like deductibles, copays and coinsurance for doctors’ visits, hospital stays and other health services. Are my favorite doctors, hospitals and pharmacies in the plan’s network? Are my prescription drugs covered and what are they going to cost? With these three pieces of critical information, consumers can begin the process of narrowing down their plan options and finding the one that’s right for their budget and specific health needs. In addition to the basics, like coverage for doctors and prescription medications, most Medicare Advantage plans offer a variety of additional benefits that can create further value. Examples include dental, vision, hearing, fitness membership, over-the-counter products, transportation to and from doctors’ visits and even healthy foods. To begin the process of selecting a plan, people should go to Medicare.gov. Once there, they can enter their zip code and see all the Medicare plans available in their area. To learn more about Aetna plans and find some resources to help you understand your Medicare options, visit AetnaMedicare.com. About Terri Swanson As President of Medicare for Aetna, a CVS Health company, Terri oversees the sales, operations and business strategy for Aetna’s robust portfolio of Medicare Advantage plans, Medicare prescription drug plans and Medicare Supplement plans. Terri is proud to lead a team that advocates for the older adult population, helping nearly 11 million Aetna Medicare members nationwide achieve their best health. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

October 23, 2023 02:08 PM Eastern Daylight Time

Video

News Release

Delivra Health Brands sees 20% increase in revenue as company posts encouraging 2023 results

Delivra Health Brands Inc.

Delivra Health Brands CEO Gord Davey joined Steve Darling from Proactive to share news the company has posted its year end 2023 financial numbers that showed for the first time in company history, Delivra Health achieved positive Adjusted EBITDA. The positive Adjusted EBITDA is attributed to various factors, including increased net revenue driven by higher sales in the USA. The company saw a 20% increase in net revenue compared to the previous year, with a significant contribution from the US market. Davey emphasized that the company's focus moving forward is to continue increasing revenue and profitability across multiple markets, including Canada, the USA, international markets, and e-commerce channels. Delivra Health's portfolio includes innovative brands like Dream Water and LivRelief, offering relief from common health issues such as sleeplessness, chronic pain, and anxiety. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

October 20, 2023 12:31 PM Eastern Daylight Time

Video

GLOBAL ENGINEER GIRLS ACHIEVES MILESTONE IN KOSOVO TOWARDS GENDER EQUALITY IN STEM

Limak

GLOBAL ENGINEER GIRLS ACHIEVES MILESTONE IN KOSOVO TOWARDS GENDER EQUALITY IN STEM Prishtine, October 18, 2023 - Global Engineer Girls (GEG), the international philanthropic initiative aiming to improve women’s representation in Science, Technology, Engineering, and Mathematics (STEM), proudly announces the graduation of 20 young women from its flagship program in Kosovo. Implemented by Limak Group in partnership with the UNDP in Kosovo, GEG Kosovo empowers young women and girls enrolled in STEM education and provides them with opportunities to gain crucial experience in a male-dominated industry. The project aims to inspire the next generation of female engineers, and highlight the strides made towards gender equality in STEM education. The graduation ceremony marked the successful completion of a year-long journey of scholarships, training, mentorship, and internships, all provided by GEG Kosovo. The ceremony also highlighted the projects undertaken by the girls during their participation in the program, including digital communication, effective team management, personal brand-building, communication, and interpersonal skills. These projects serve as compelling evidence that extending opportunities to girls is a vital way to prepare them for successful futures in the STEM world. President of Kosovo, Vjosa Osmani, in her speech, mentioned, "We must ensure that all our bright minds have equal opportunities to pursue the education of their choice. We need these equal minds in order to address the critical issues of our time, such as climate change and AI. We cannot afford to exclude half of our population from the most pressing challenges of our era. It is imperative to collaborate and work together to achieve equality more swiftly. These young girls serve as clear examples of the potential within our youth. It is our duty to ensure that young women and girls feel empowered to pursue their dreams, regardless of the path they choose. They must harbour no fear or hesitation in stating, 'I want it, and I will make it.' Every girl holds a guaranteed place in our future. I encourage each girl to carry forward the legacy of GEG.” Chair of Limak Holding and Limak Foundation, Ebru Özdemir, said: “It's truly an important milestone for GEG and our vision at Limak. I’m thrilled to see the progress of the GEG Kosovo participants over the past year, and I am certain they all have a bright future ahead of them. Engineering isn’t a man’s world anymore, so it is our responsibility to continue to create opportunities for young women to succeed in STEM by supporting them in their studies and careers.” GEG Kosovo extends its gratitude to its supporters, mentors, parents, and volunteers, who have enabled the success of this program. Their collective efforts have empowered young girls to overcome challenges, build confidence, and unlock their full potential. Moving forward, GEG Kosovo remains committed to expanding and enhancing its programs to reach even more young girls, empowering them to break down barriers and become leaders in STEM fields. About Global Engineer Girls Global Engineer Girls (GEG) is an international philanthropic initiative that aims to inspire the next generation of female engineers. The inception of GEG was driven by Limak Group of Companies' culture and its Chairperson's, Ebru Özdemir's, deep personal commitment to improving women's representation in STEM. GEG provides girls and women with education, mentorship and career opportunities in Turkey, North Macedonia, Kosovo, Kuwait and beyond. GEG's predecessor, the Engineer Girls of Turkey (EGT), was launched in Turkey in 2015. Since its inception in 2015, the GEG university programme has benefited 710 young women by providing support for female students enrolled in chemical, civil, computer, electrical- electronic, environmental, industrial, and mechanical engineering departments in Turkish universities. This support has included funded scholarships and mentoring by hundreds of professional volunteers, as well as online training programs, soft skills and English language courses, internships, and employment opportunities at Limak's companies and partner companies. About Global Engineer Girls Kosovo Global Engineer Girls (GEG) Kosovo was established in 2022, in partnership with Limak Kosovo and United Nations Development Programme in Kosovo. GEG Kosovo currently operates in three public universities, covering bachelor and master's programs in engineering. UNIVERSITY OF PRISHTINA "HASAN PRISHTINA", UNIVERSITY OF APPLIED SCIENCES IN FERIZAJ, UNIVERSITY OF MITROVICA "ISA BOLETINI" Note to editors: High-resolution images from the graduation ceremony are available in the attachment. Contact Details Highgate Advisory Ltd. Iulia Trandafir +44 7516 787557 iulia@highgate.ltd

October 19, 2023 09:59 AM Central Daylight Time

How the Worker Shortage in Healthcare Could Impact Your Health

YourUpdateTV

A recent Harris Poll found that 68% of Americans are worried that the worker shortage in healthcare could have an impact on their own health. Recently, spokespeople from the American Academy of Physician Associates (AAPA), participated in nationwide satellite media tour to discuss the impact of the worker shortage in healthcare and how physician associates, or PAs, can help increase access to care. A video accompanying this announcement is available at: https://youtu.be/4XRJDYFt3R0 Healthcare workforce shortages are having a profound impact on patient access to care, with patients reporting feeling frustrated and anxious about their ability to get the care they need when they need it. The recent Harris Poll survey found that nearly three-fourths of all U.S. adults say the healthcare system isn’t meeting their needs, and more than 1 in 4 gave the healthcare system a failing grade. One of the most concerning ways provider shortages are impacting patients is the amount of time it is taking to get a needed health appointment. Patients are waiting an average of 3.9 weeks for a medical appointment. As one of the fastest growing medical professions in the country, PAs can make a positive and lasting impact on patient care. An overwhelming 91% of U.S. adults believe that PAs are part of the solution to addressing the shortage of healthcare providers and additionally, 90% of patients say that PAs increase access to care and make medical appointments easier to obtain. One significant issue is that PA practice laws vary by state across the country. The challenge here is that in far too many states, these laws haven't been updated to reflect the way medical care is delivered today. A resounding 91% of U.S. adults support updating PA practice laws and the mandate is clear: The public wants the healthcare system to be as efficient and accessible as possible and updating these laws is a win-win for patients and the entire healthcare system. For more information, please visit aapa.org/patientexperience. About the American Academy of Physician Associates (AAPA) AAPA is the national membership organization for all physician associates/physician assistants (PAs). PAs are licensed clinicians who practice medicine in every specialty and setting. Trusted, rigorously educated and trained healthcare professionals, PAs are dedicated to expanding access to care and transforming health and wellness through patient-centered, team-based medical practice. PA has been named one of the best jobs overall and one of the best healthcare jobs for the sixth year in a row by U.S. News & World Report The PA profession ranked number three this year in Best STEM jobs. Learn more about the profession at aapa.org and engage through Facebook, LinkedIn, Instagram, and Twitter. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

October 18, 2023 02:31 PM Eastern Daylight Time

Video

Mydecine Innovations Group gearing up for human trials after completing Aquis listing

Mydecine Innovations Group Inc

Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) CEO Joshua Bartch speaks to Thomas Warner from Proactive London about the biotechnology company's ambitious goals in the psychedelic medicine sector. Bartch explains that Mydecine focuses on developing "second generation" drugs derived from first-generation psychedelic molecules like LSD, MDMA, and psilocybin. Their aim is to enhance the efficacy of these drugs while addressing challenges like half-life, scalability, cost, and accessibility. He emphasises the company's efforts to make these drugs more adaptable to the existing medical infrastructure, aiming to increase accessibility by five to tenfold. Highlighting the UK's progressive stance on psychedelics, Bartch announced Mydecine's recent listing on London's Aquis Exchange, emphasising the potential benefits for both current and future shareholders. The company is gearing up for phase one human trials of their lead drug candidates by early 2024, with their MYCO-006, a second-generation MDMA analogue, showing promising results in preclinical studies. Addressing perceptions of psychedelic medicine industry, Bartch notes a significant shift, saying that major biotech investors and institutions, once skeptical, are now showing keen interest. Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com

October 18, 2023 06:15 AM Eastern Daylight Time

Video

Bristol Myers Squibb Joins Big Pharma’s Race to Dominate Oncology

MarketJar

Leading pharmaceutical companies are diving headfirst into oncology, sparking a buzz in the cancer treatment world. Bristol Myers Squibb is the latest company to join the movement, announcing its plan to acquire Mirati Therapeutics in a deal valued at up to $5.8 billion 1. This strategic move aims to enhance BMS's oncology portfolio with Mirati's compound, MRTX1719, which holds promise for certain lung cancers, was a key draw. The acquisition received unanimous approval from both companies' boards of directors. Bristol Myers Squibb's CFO and CEO-elect, Chris Boerner, highlighted the importance of this move, emphasizing that the acquisition of Mirati is another substantial step in their endeavor to expand their diversified oncology portfolio and reinforce Bristol Myers Squibb's pipeline for the latter half of the decade and beyond. Eli Lilly, a prominent American pharmaceutical giant, is another major player that has joined this trend with its acquisition of cancer therapy company Point Biopharma Global, for $1.4 billion 2. Point specializes in radioligand therapies, particularly for advanced-stage prostate cancer patients unresponsive to hormonal treatments. Pfizer and Amgen also made the headlines earlier this year with strategic acquisitions of small oncology companies. These multi-billion-dollar transactions, combined with rising cancer awareness efforts and an uptick in global cancer incidences, have rocketed the cancer therapy market to a whopping $158 billion in 2020. This trajectory is only expected to rise, targeting a 9.15% CAGR and aiming for a $268 billion value by 2026. 3 Among the oncology companies developing therapies for this growing market is Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF), a Canadian biopharmaceutical company specializing in immune-oncology therapies and drug delivery technologies, could find themselves in the same spot as Mirati Therapeutics or Point Biopharma Global. Defence Therapeutics is dedicated to advancing the next generation of vaccines, anticancer therapeutics and ADC products using its proprietary platform. Central to Defence Therapeutics ' platform is the Accum® technology, which enables the precise delivery of biomedicines in their intact form to target cells. This innovation promises increased efficacy and potency against severe illnesses like cancer and infectious diseases. Breakthrough AccuTOX ™ -Chitosan Formulation Shows Lymphoma Treatment Potential Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF) just reported a significant breakthrough. Their novel AccuTOX ™ -chitosan encapsulated formulation has proven effective in inhibiting the growth of established solid lymphomas, resulting in gradual tumor shrinkage over time. The study had two primary goals: firstly, to determine if AccuTOX ™ could be successfully administered systemically when encapsulated in chitosan-based nanoparticles, and secondly, to assess whether this approach could work in synergy with commonly used immune-checkpoint blockers in oncology. The formulation was administered twice with a two-week interval, and the treated animals were monitored for up to 40 days. Impressively, the tumors in animals receiving AccuTOX ™ -Chitosan injections, along with co-administered anti-PD-1, regressed, and the animals exhibited prolonged survival rates. “The AccuTOX ™ molecule can be toxic if delivered unconjugated and/or systemically. The Defence team was able to bypass this limitation by encapsulating it into chitosan-based nanoparticles,” explained Sebastien Plouffe, CEO of Defence Therapeutics. “This is a simpler and cheaper method compared to the use of antibodies, and may represent a key component of Defence’s future encapsulation strategies''. Chitosan, a linear polysaccharide composed of deacetylated and acetylated units, has a wide range of commercial and biomedical applications. Aside from its uses in agriculture and industry, it is employed in bandages to reduce bleeding and as an antibacterial agent. Chitosan can also facilitate drug delivery through the skin. Leveraging it as a delivery vehicle for unconjugated Accum® or its variants has the potential to revolutionize molecular medicine. This approach could increase compound specificity at tumor sites while minimizing the required dosage and, consequently, reducing associated side effects. By innovatively encapsulating the AccuTOX ™ molecule, Defence Therapeutics has not only achieved remarkable tumor regression but also highlighted a potential direction for future molecular medicine endeavors. As researchers and companies continue to push boundaries in the quest for cancer solutions, this advancement underscores the immense potential of integrating existing materials like chitosan with novel therapeutic agents. It's a beacon of hope in the ongoing fight against lymphoma and a testament to the unyielding spirit of medical innovation. For more information about Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF) and its Accum® technology, click here or visit their website. Footnotes: [1] https://www.foxbusiness.com/markets/bristol-myers-squibb-buy-cancer-drugmaker-mirati-therapeutics-billion-deal [2] https://www.forbes.com/sites/anafaguy/2023/10/03/eli-lilly-acquiring-cancer-therapy-developer-for-14-billion-a-nearly-90-premium/ [3] https://www.mordorintelligence.com/industry-reports/cancer-therapy-market Disclosure: 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Defence Therapeutics Inc. Market Jar Media Inc. has or expects to receive from Defence Therapeutics Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) ninety six thousand five hundred US dollars for 30 days (21 business days). 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Defence Therapeutics Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Defence Therapeutics Inc.’s industry; (b) market opportunity; (c) Defence Therapeutics Inc.’s business plans and strategies; (d) services that Defence Therapeutics Inc. intends to offer; (e) Defence Therapeutics Inc.’s milestone projections and targets; (f) Defence Therapeutics Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Defence Therapeutics Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Defence Therapeutics Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Defence Therapeutics Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Defence Therapeutics Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) the accuracy of budgeted costs and expenditures; (e) Defence Therapeutics Inc.’s ability to attract and retain skilled personnel; (f) political and regulatory stability; (g) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (h) changes in applicable legislation; (i) stability in financial and capital markets; and (j) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Defence Therapeutics Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Defence Therapeutics Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Defence Therapeutics Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Defence Therapeutics Inc.’s business operations (e) Defence Therapeutics Inc. may be unable to implement its growth strategy; and (f) increased competition.Except as required by law, Defence Therapeutics Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Defence Therapeutics Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Defence Therapeutics Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Defence Therapeutics Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Defence Therapeutics Inc. or such entities and are not necessarily indicative of future performance of Defence Therapeutics Inc. or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

October 17, 2023 09:00 AM Eastern Daylight Time

Image

AI startup Leucine nets $7M to level up Pharma manufacturing compliance to keep pace with drug innovation

Leucine

Pharmaceutical manufacturing is the lynchpin to getting drug innovation to people. While compliance protocols are key to ensuring the smooth operation of the industry, they are beset by processes that are not fit for purpose and are hindering their ability to deliver life-saving drugs faster. Suffocated by paper-based records and legacy systems, the large-scale manufacturing of drugs is being hampered. It’s little wonder that a staggering 2 out of 3 FDA warnings are for non-compliance related to procedures not being followed appropriately, unclear work instructions of methods, failure to review equipment usage logs, and lack of shared procedures between Quality Assurance and production departments. These matters are often missed and go unnoticed because of the conventional paper-based systems in the pharmaceutical industry. Helping to make pharmaceutical manufacturing compliant, safer, and faster, tech startup Leucine is today announcing a $7M series A funding round led by Ecolab Inc., a strategic investor, to scale its Compliance Cloud platform globally. This round also saw participation from all existing investors, including Pravega Ventures, Axilor Ventures, Techstars, and angels. Vivek Gera, founder, and CEO of Leucine, commented: “Paper-based manufacturing records are the industry's achilles' heel, fueling not only regulatory nightmares but also ballooning production costs and inefficiencies. The legacy solutions are no better, with their extremely long implementation cycles and rigid, siloed applications that leave manufacturers in a lurch.” Leucine's Compliance Cloud serves as a digital twin of the pharma manufacturing shop floor, bringing real-time performance monitoring, compliance management, and actionable insights to the table. For pharma manufacturers, leveraging data can mean the difference between a successful batch and a costly recall. What differentiates Leucine from some of the legacy digitization tools is its AI-driven capabilities designed not only to digitize pharma manufacturing workflows faster but also to provide proactive insights that enable pharma companies to stay compliant and produce faster and in a cost-effective manner. Leucine's platform can be implemented in 8 weeks. This speed of implementation becomes possible because of the proprietary AI-enabled digital process builder based on Large Language Models (LLMs) that rapidly digitizes paper SOPs into execution-ready digital formats. "Our models are trained on a wealth of pharma data, which allows the platform to create custom workflows enriched with GxP compliance measures, enabling us to deliver unparalleled value at breakneck speed," added Vivek Gera. A batch execution procedure is the single most important document in pharma manufacturing. This rapid digitization capability reduces the digitization cycle of a batch record from 6-8 months to 3-5 days. Leucine is currently deployed at over 30 companies in over 300 pharma manufacturing facilities across 10 countries, including the US, India, Brazil, Mexico, UAE, and others. The company is today also announcing the beta launch of Leucine10x, a groundbreaking AI framework designed to serve as a co-pilot in pharmaceutical manufacturing processes. Leucine10x will revolutionize how decision-making is done in pharma manufacturing, enabling Production and Quality Assurance teams to achieve their organization goals with ease and confidence. Built on proprietary LLM technology, Leucine10x offers an army of AI co-pilots that perform highly specialized tasks such as digitizing paper-based SOPs, creating a digital twin of the shop floor, collaborating with Production Managers in creating dynamic production plans, thus ensuring on-time batch delivery. Most significant is their ability to speed up Root Cause Analysis (RCA) of deviations in the manufacturing process by quickly analyzing data, including text-based records, logs, and even staff interview transcripts, to identify potential issues or patterns that might not be readily apparent. Mustaq Singh Bijral, Co-founder and CPO of Leucine, said: "We're excited to share that Leucine10x is already operational in select customer facilities under a trusted tester agreement. The response has been incredibly positive, and due to high demand, we're currently enrolling new customers through a waitlist". The funding round will support Leucine in refining its AI capabilities and making its AI Co-pilot a trusted partner to the production and quality managers on the shop floor and in expanding its reach to more facilities and customers. “Vivek and Mustaq have been relentless in their mission to make pharma manufacturing safer. This latest funding round will enable Leucine to bring the power of LLMs and associated technologies to make significant advances in pharma manufacturing. We couldn’t be happier to support them in this quest” said Rohit Jain, Co-founder and Partner at Pravega Ventures. Pravega Ventures also invested in the Seed round of Leucine. Vivek Gera remarked: "We're just scratching the surface; our vision is to leverage AI and technology to bring safe medicine to patients across the world” About Leucine Leucine is at the forefront of digitizing pharmaceutical manufacturing, leveraging cutting-edge AI technologies to bring unprecedented efficiency and compliance to the shop floor. Our innovative solutions, from Batch Planning to Batch Release, aim to modernize traditional procedures, replacing paper-based records with a seamless, digital-first approach. Trusted by industry leaders, Leucine not only streamlines the manufacturing process but also delivers actionable insights through its AI-driven analytics dashboard, empowering pharma companies to produce safer and more effective medicines. Leucine is headquartered in New Jersey, United States. For more information, visit https://www.leucine.io/ About Pravega Ventures Pravega Ventures is an early stage Venture Capital fund that partners with passionate founders, who are leveraging technology to either disrupt existing markets or create new ones. Contact Details Leucine Sampada Bhootna +91 81458 07848 sampada.bhootna@leucinetech.com Company Website https://www.leucine.io/

October 16, 2023 09:00 AM Eastern Daylight Time

Image

Don't Let Osteoarthritis Hold You Back

YourUpdateTV

Do you or someone you know have pain in your joints or stiffness when doing daily activities? These symptoms may be related to a common condition called osteoarthritis and it affects more than 32.5 million adults in the U.S. Recently, Dr. Sherri Betz, PT, DPT, a physical therapist and spokesperson for the American Physical Therapy Association, conducted a satellite media tour to talk about how physical therapy can treat and help people manage the symptoms of osteoarthritis. A video accompanying this announcement is available at: https://youtu.be/7OIFKIUNuxA Osteoarthritis, or OA, is the most common form of arthritis. Some people call it degenerative joint disease or “wear and tear” arthritis. It occurs most frequently in the hands, hips, and knees. ( CDC ). The signs and symptoms of OA can vary, so the approach to care also will vary. Common symptoms include stiffness in joint(s), pain during activity, and cracking or creaking noise around the joint. Physical therapists work with their patients and clients to develop treatment plans specific to each person’s needs and goals. Although osteoarthritis cannot be reversed, osteoarthritis symptoms often can be effectively managed through conservative approaches like exercise and treatment by a physical therapist. Regular physical activity can help maintain and improve movement and function and reduce joint pain for people with arthritis. The knees are among the joints most commonly affected by osteoarthritis, with nearly 12.4 million people ages 65 or older having symptomatic knee OA. Some individuals may receive multiple steroid injections to treat their OA; however, research shows that physical therapy is an effective treatment option for OA of the knee. A new report just released by the American Physical Therapy Association found that, compared with injections, physical therapy for OA of the knee offers similar improvements sooner. The report also calculated the economic impact of choosing physical therapy for OA of the knee over steroid injections and found that doing so saves close to $14,000, including all the hidden costs of your time, pain, missed life events, and the dollars paid for services. For more information visit ChoosePT.com About Sherri Betz, PT, DPT APTA spokesperson Sherri Betz is a physical therapist and director of TheraPilates Physical Therapy in Louisiana, specializing in geriatrics and osteoporosis. Betz is devoted to improving awareness about geriatric exercise, bone health, and safe yoga and Pilates-based exercise through professional and consumer education as well as through the promotion of low-cost, on-site, and virtual community exercise programs for older adults. She serves on the Bone Health & Osteoporosis Foundation’s Exercise and Rehabilitation Activities Council as APTA’s liaison, as well as the American Bone Health’s Professional Education Committee. Betz also serves as chair of Pilates Method Alliance's Research Committee and is past chair of the PMA Certification Commission and board vice president. She is a graduate of Louisiana State University’s physical therapy program and received a Doctor of Physical Therapy degree from EIM Institute of Health Professions. She is a board-certified clinical specialist in geriatric physical therapy. She also is a nationally certified NPCP Pilates teacher and a certified exercise expert for aging adults. Betz is a recipient of both the PMA's Deborah Lessen award for her many years of dedicated service to PMA and the APTA Geriatrics' Lynn Phillippi Advocacy for Older Adults award. She has published numerous articles, authored book chapters, produced videos, and speaks internationally about exercise for osteoporosis. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

October 12, 2023 11:46 AM Eastern Daylight Time

Video

Demand for Online Writing and Content Creation Jobs Intensifies, finds Freelancer.com

FREELANCER.COM

Freelancer.com (ASX: FLN) (OTCQX: FLNCF), the world’s largest freelancing and crowdsourcing marketplace by number of users and jobs posted, today released its quarterly report revealing the most in-demand online jobs on the platform for Q3 2023. The Fast 50 Q3 2023 report, a quarterly dataset ranking the fastest growing and falling jobs on the platform, analyzed over 277,000 jobs posted by employers to Freelancer.com between July and September 2023. According to the data, the fastest growing freelance jobs by percentage growth in Q3 2023 were mostly writing, content creation and marketing related. As AI continues to advance, the need for human creativity remains strong. Employers are once again seeking freelancers to support with Creative Writing and Content Writing projects, which are up 22.4% and 19.4% respectively. A surge in demand for writing skills across the platform means there were more than 10,000 additional writing projects available in Q3 2023, which were already a trending skill evident in the previous quarter. The Q3 2023 data also indicates a consistent trend in businesses seeking freelance marketing support, with Search Engine Marketing (up 24.1%), Videography (up 17.4%) and Telemarketing (up 16.5%) seeing notable growth across the quarter. This aligns with the previous quarter's emphasis on business marketing activities. “Our Freelancer Fast 50 Report is a forward leading indicator of the skills and expertise businesses need today. Artificial Intelligence is powering a boom in content creation, particularly focusing on writing, marketing and video production skills” said Matt Barrie, Chief Executive at Freelancer. “Generative AI is superskilling freelancers and their ability to produce extremely high quality content and faster than ever before. Tools like ChatGPT and Bard have changed the game when it comes to producing and refining written content, while advances in video AI such as Runway Gen-2, HeyGen and Pika Labs means that video production and editing can be done with a click of a button.” Growth in skills like User Interface / IA (up 17.4% from 3,071 to 3,607) and UX / User Experience (up 13.9% from 1,193 to 1,359) highlight the importance of user-centric design in today's digital landscape. Data Mining (up 14.9% from 2,374 to 2,728) and Data Processing (up 10% from 11,013 to 12,115) were also amongst the top growing jobs. These skills are often associated with Sales functions and Lead Generation, which are also growing in the quarter, up 13.3% and 11.4% respectively. By leveraging freelancers to research leads, businesses can operate more efficiently and focus more on relationship building in the sales process. Design, Marketing and Video Creation Jobs Lead Year-on-Year Growth Several skills have surged in demand when comparing Q3 2022 and Q3 2023. Jobs for User Interface (UI) Design have doubled, growing by 101.9% to 3,607 from 1,786 in the same period last year. Search Engine Marketing jobs grew 80.4% (from 1,597 to 2,881) and Videography jumped by 77.1% (from 2,716 to 4,809). Fastest Falling Jobs of Q3 2023 The recent data highlights a shift in the demand for specific technical skills, which saw a significant increase last year as many tech companies laid off technical staff. There's a noticeable decline in jobs for certain established programming languages and frameworks. For instance, Matlab and Mathematica saw a 25.1% decrease (from 1,349 to 1,011 jobs). Similarly, projects requiring skills in AngularJS jobs dropped by 23.5% (from 1,722 to 1,318), while those requiring Django experts experienced a decline of 23.4% (from 1,216 to 932). C Programming, C++ Programming, and Python, which were all in-demand skills in Q3 2022, also all decreased on the platform in Q3 2023. While algorithms remain integral to many processes, there's been a reduction in specialized roles in this domain. This trend is evident in the decrease in demand for Algorithm skills, which saw a decrease of 22.5% (from 1,438 to 1,114 jobs). This might be a consequence of the advent of more intuitive tools and platforms that simplify algorithmic tasks. __________________________________________________________________________________________________ Fast 50 Q1 2023 - Data Analysis Writing Jobs Show No Sign Of Slowing Down The introduction of highly sophisticated and powerful generative AI tools have led many experts and commentators to predict that skills such as writing will be replaced by AI. However, the latest Fast 50 Q3 data demonstrates that writing jobs are here to stay, as content writing, creative writing, copy typing and ghostwriting jobs increase by more than 20% over the last quarter. These skills continue to flourish after reporting growth in the previous quarter on Freelancer.com, with Creative Writing ranked as the fastest growing skills in Q2 2023 (up 58%, from 1,868 to 2,961). An Increase in writing skills for two quarters in a row suggest that businesses are placing more emphasis on content creation by hiring freelancers to write articles and produce creative content. Copy Typing, the fastest growing skill for Q3’23 (up 28.7% from 6,381 to 8,213) encompasses all types of jobs from data entry to helping write e-books to transcription and typist projects. While technical projects do require degrees and past experience, most copy typing jobs can be performed by freelancers with no prior knowledge, making it a lucrative side hustle for freelancers globally. AI’s Impact on Whitecollar Jobs While writing jobs continue to flourish over the past 6 months, there is a need to understand how generative AI will impact jobs and various freelancing skills. In a longform essay titled ‘ AI know what you did last summer ’, Freelancer.com CEO Matt Barrie discusses the bleeding edge of AI technology and how he predicts these will go on the shape white-collar jobs. Barrie suggests that to be competitive in a world of AI, workers will need to adapt or move up the stack: “Those in white collar jobs will need to move ‘up the stack’. Illustrators become cinematographers. Writers become editors. Software developers become product managers. Grad students now run a research group.” Barrie also highlights that there is a major opportunity for freelancers, arguing that AI-powered freelancers will ultimately be the winners as they have the ability to compete against middle class workforces all around the world. AI’s impact on work productivity is evident in a recent AI study conducted by Freelancer.com which found that in a survey of over 1,300 US workers, a majority of those US workers (75%) are using generative AI tools in their work. One in three (33%) workers are using AI tools all the time in their work, while one quarter of US workers (25%) are using these tools sometimes and one sixth (16%) admit to never using AI at work. Marketing & Video Production Sustain Growth, Growing Every Quarter in 2023 Marketing and Video Production skills are one of the most in-demand skill categories on the platform, with data showing they’ve now grown every quarter since the beginning of the year. Search Engine Marketing (up 24.1%, from 2,321 to 2,881) ranked as the third fastest growing skill on the platform. Telemarketing (up 16.5%, from 1,054 to 1,228) has grown in Q3 as businesses turn towards more traditional marketing tactics. Sustained growth in different types of marketing skills means there are many opportunities for skilled freelancers to find unique projects on the platform. As for video production, not only is the skill up quarter-on-quarter, but both Video Production and Videography have almost doubled when compared to the same time last year, up 58.1% and 77.1% respectively. The surge in freelancer video production jobs can be attributed to the booming demand for online content, especially on platforms like YouTube (up 10.3%, from 1,174 to 1,295 jobs in Q3) and TikTok. As content is a staple in many marketing strategies, businesses are turning to freelancers to help them produce content, boosting this as a potential category for workers. Businesses Delegating Sales Functions to Freelancers As found in the Freelancer.com World’s Most Boring Job research, businesses often delegate research heavy tasks to on-demand freelancers. In turn, this allows businesses the ability to operate more efficiently and focus on more impact-based tasks. A unique trend uncovered in the Fast 50 Q3 2023 shows that businesses are leaning on freelancers to help with the research portion of the sales function. Sales and Lead Generation ranked as some of the fastest growing jobs in the quarter, up 13.3% and 11.4% respectively. Interestingly, Sales and Lead Generation both featured in the top 25 fastest growing jobs in Q2 2023. Growth in sales and lead generation is an example of how businesses are employing freelancers to help them streamline the sales process. ###### Freelancer Fast 50 The Freelancer Fast 50 report is the world’s largest forward indicator of trends in online jobs related to industries, technologies, products, and companies. The data is based on 277,000 jobs posted to the Freelancer.com platform between July 1 to September 30 2023. Fast 50 Q3 2022 vs Q3 2023 Fast 50 Q2 2023 vs Q3 2023 Data About Freelancer Twelve-time Webby award-winning Freelancer.com is the world’s largest freelancing and crowdsourcing marketplace by total number of users and projects posted. More than 69 million registered users have posted over 23.1 million projects and contests to date in over 2,000 areas as diverse as website development, logo design, marketing, copywriting, astrophysics, aerospace engineering and manufacturing. Freelancer owns Escrow.com, the leading provider of secure online payments and online transaction management for consumers and businesses on the Internet with over US$5 billion in transactions secured. Freelancer also owns Freightlancer & Loadshift, enterprise freight marketplaces with over 550 million kilometers of freight posted since inception. Freelancer Limited is listed on the Australian Securities Exchange under the ticker ASX:FLN and is quoted on OTCQX Best Market under the ticker FLNCF. Forward-looking statements This document contains certain "forward-looking statements". The words "anticipate", "believe", "expect", "project", "forecast", "estimate", “outlook”, “upside”, "likely", "intend", "should", "could", "may", "target", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance, including Freelancer’s FY23 outlook, are also forward-looking statements, as are statements regarding Freelancer’s plans and strategies and the development of the market. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of Freelancer, which may cause actual results to differ materially from those expressed or implied in such statements. Freelancer cannot give any assurance or guarantee that the assumptions upon which management based its forward-looking statements will prove to be correct or exhaustive beyond the date of its making, or that Freelancer's business and operations will not be affected by other factors not currently foreseeable by management or beyond its control. Such forward-looking statements only speak as at the date of this announcement and Freelancer assumes no obligation to update such information. The release, publication or distribution of this document in jurisdictions outside Australia may be restricted by law. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. Contact Details Freelancer.com Marko Zitko +61 404 574 830 mzitko@freelancer.com

October 12, 2023 07:09 AM Pacific Daylight Time